index	sentence	Gene	Mutation
0	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Leu19Phe
1	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Lys117Asn
2	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Ala146Thr
3	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Arg164Gln
4	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Lys117Asn
5	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Ala146Thr
6	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Leu19Phe
7	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Arg164Gln
8	Ras proteins regulate signal transduction by activating a number of downstream effector proteins, including the cytoplasmic serine/threonine protein kinase B-Raf (Figure 1)	 protein kinase B-Raf	serine/threonine
9	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	T to A
10	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	valine to glutamic acid
11	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	V600E
12	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	T to A
13	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	valine to glutamic acid
14	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	V600E
15	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12V
16	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12D
17	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G13D
18	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	Q61H
19	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	L19F
20	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	K117N
21	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	A146T
22	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	R164Q
23	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12V
24	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12D
25	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G13D
26	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	Q61H
27	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	L19F
28	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	K117N
29	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	A146T
30	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	R164Q
31	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12V
32	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12D
33	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G13D
34	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	Q61H
35	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	L19F
36	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	K117N
37	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	A146T
38	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	R164Q
39	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12V
40	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12D
41	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G13D
42	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	Q61H
43	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	L19F
44	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	K117N
45	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	A146T
46	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	R164Q
47	500 mug of cell lysate from each sample was incubated with 10 mug of Raf-1 RBD agarose at 4 C for 30 min with gentle rocking	Raf-1	C for 30
48	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
49	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
50	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12C
51	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
52	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
53	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
54	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
55	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
56	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
57	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
58	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
59	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12C
60	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
61	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
62	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
63	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
64	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
65	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
66	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	C for 5
67	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	C for 5
68	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	G57T
69	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	Leu19Phe
70	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	V600E
71	Together, these K-Ras mutations and the B-Raf V600E mutation increase overall Ras pathway mutation frequency from 27.4 to 37.8%	K-Ras	V600E
72	Together, these K-Ras mutations and the B-Raf V600E mutation increase overall Ras pathway mutation frequency from 27.4 to 37.8%	B-Raf	V600E
73	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
74	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
75	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
76	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
77	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
78	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
79	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
80	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
81	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
82	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
83	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
84	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
85	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
86	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
87	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
88	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
89	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
90	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
91	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
92	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
93	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
94	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
95	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
96	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
97	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	G12V
98	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	L19F
99	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	K117N
100	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	A146T
101	In contrast, the R164Q mutation, like wt K-Ras, was not GTP-bound.	K-Ras	R164Q
102	It is interesting to note that the codon 12 mutants were most similar to wt K-Ras, whereas the K117N and A146T mutants clustered with the activating codon 13 and codon 61 hotspot mutants	K-Ras	K117N
103	It is interesting to note that the codon 12 mutants were most similar to wt K-Ras, whereas the K117N and A146T mutants clustered with the activating codon 13 and codon 61 hotspot mutants	K-Ras	A146T
104	The presence of R164Q in cluster 2, rather than in cluster 1 with wt K-Ras was therefore initially surprising, but suggests that the R164Q mutation also has an 'activating' phenotype, albeit attenuated relative to the other mutations studied.	K-Ras	R164Q
105	The presence of R164Q in cluster 2, rather than in cluster 1 with wt K-Ras was therefore initially surprising, but suggests that the R164Q mutation also has an 'activating' phenotype, albeit attenuated relative to the other mutations studied.	K-Ras	R164Q
106	However, there were examples of genes that were induced by all of the mutants studied, including the protein tyrosine phosphatase Ptpre and the Rho GTPase activating protein Arhgap6, and multiple examples of genes induced or repressed by all of the mutants with the exception of R164Q	Ptpre	R164Q
107	However, there were examples of genes that were induced by all of the mutants studied, including the protein tyrosine phosphatase Ptpre and the Rho GTPase activating protein Arhgap6, and multiple examples of genes induced or repressed by all of the mutants with the exception of R164Q	Arhgap6	R164Q
108	RFLP analysis of B-Raf V599E mutation	Raf	V599E
109	The B-Raf V599E mutation was detected using a novel RFLP assay, where the presence of the mutation destroyed a recognition site for the restriction enzyme TspRI	Raf	V599E
110	Samples without the B-Raf V599E mutation were digested to produce bands of 124, 78 and 22 bp, whereas samples homozygous for the V599E mutation produced bands of 202 and 22 bp	B-Raf	V599E
111	Samples without the B-Raf V599E mutation were digested to produce bands of 124, 78 and 22 bp, whereas samples homozygous for the V599E mutation produced bands of 202 and 22 bp	B-Raf	V599E
112	Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation	HRAS	p.Lys117Arg
113	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	L19F
114	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	K117N
115	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	A146T
116	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	R164Q
117	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	G12V
118	The K-Ras G12V construct was included as a positive control for K-Ras protein in the active GTP-bound conformation.	K-Ras	G12V
119	The K-Ras G12V construct was included as a positive control for K-Ras protein in the active GTP-bound conformation.	K-Ras	G12V
